Recent News

• 04.23.2025 - Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 04.23.2025 - Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
• 04.08.2025 - Stifel 2025 Virtual Targeted Oncology Forum
• 03.27.2025 - Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.27.2025 - Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.25.2025 - Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
• 03.25.2025 - Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 03.03.2025 - TD Cowen 45th Annual Health Care Conference
• 02.24.2025 - Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Recent Filings

• 03.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.27.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2025 - 8-K Current report
• 03.27.2025 - EX-99.1 EX-99.1
• 03.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.14.2025 - 144 Report of proposed sale of securities
• 03.03.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors